Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 9/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | FPR2 | P25090 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.97 |
| ▸ | SCN1A | P35498 | 3/20 | 0.97 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695235 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| SCHEMBL12648358 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| SCHEMBL9927435 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL30603259 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL30165585 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL897995 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL9895302 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL29734979 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| SCHEMBL1929636 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 | |
| Hydrochloric Acid SCHEMBL15720860 | 0.97 | CYP3A4 (0.95) | CYP3A4CYP1A2CYP2C19CYP2C9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | claimed |
| WO-2023164606-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-31 | — | — | WO | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| US-20210369677-A1 | SMALL MOLECULE ACTIVATORS OF POLYCYSTIN-2 (PKD2) AND USES THEREOF | UNIV NORTHWESTERN (US) | 2021-12-02 | — | — | US | claimed |
| CN-112689758-A | Device and method for examining the effect of a drug on microorganisms | ESSENLIX公司 | 2021-04-20 | — | — | CN | claimed |
| US-20200399675-A1 | DEVICES AND METHODS FOR EXAMINING DRUG EFFECTS ON MICROORGANISMS | ESSENLIX CORPORATION (US) | 2020-12-24 | — | — | US | claimed |
| WO-2019028133-A1 | DEVICES AND METHODS FOR EXAMINING DRUG EFFECTS ON MICROORGANISMS | ESSENLIX CORPORATION (US) | 2019-02-07 | — | — | WO | claimed |
| EP-2825173-B1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CHILDRENS MEDICAL CENTER (US) | 2018-10-10 | — | — | EP | claimed |
| US-9976172-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2018-05-22 | — | — | US | claimed |
| WO-2012104788-A2 | ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-09 | — | — | WO | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | claimed |
| EP-0428754-B1 | HAIR GROWTH STIMULANT | SHISEIDO CO LTD (JP) | 1994-05-25 | — | — | EP | claimed |
| EP-0428754-A1 | HAIR GROWTH STIMULANT | SHISEIDO COMPANY LIMITED (JP) | 1991-05-29 | — | — | EP | claimed |
| EP-0305008-A2 | Tumor or cancer cell killing therapy and agents useful therefor | OXI-GENE, INC. (US) | 1989-03-01 | — | — | EP | claimed |
| US-4681899-A | Method of preventing the growth of malaria parasites in erythrocytes | HARTFORD LIFE INSURANCE COMPANY, A CORP. OF CT | 1987-07-21 | — | — | US | claimed |
| US-4476141-A | Use of N-(6 aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6 aminohexyl)-5-chloro-2-naphthalenesulfonamide, and N-(6 aminohexyl)-5-bromo-2-naphthalenesulfonamide as vaginal contraceptives | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-10-09 | — | — | US | claimed |
| EP-0102162-A1 | Use of calmodulin binding drugs for preventing pregnancy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-03-07 | — | — | EP | claimed |
| WO-1984000297-A1 | USE OF CALMODULIN BINDING DRUGS AS VAGINAL CONTRACEPTIVES | UNIV GEORGIA RES FOUND (US) | 1984-02-02 | — | — | WO | claimed |
| US-4419366-A | Use of N-(6 aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6 aminohexyl)-5-chloro-2-naphthalenesulfonamide, or N-(6 aminohexyl)-5-bromo-2-naphthalenesulfonamide in the uterus to prevent pregnancy | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1983-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369677-A1 | SMALL MOLECULE ACTIVATORS OF POLYCYSTIN-2 (PKD2) AND USES THEREOF | PKD2, PKD1, GLS | CYP3A4 4880/4885CYP1A2 4789/4885CYP2C19 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.